Where does Interquim, S.A. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Interquim, S.A. ranks #16,900 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Interquim, S.A. hold?

Interquim, S.A. holds 17 US utility patents granted between 2015 and 2025, spanning 14 technology areas.

What is Interquim, S.A.'s Innovation Score?

Interquim, S.A. has an Innovation Score of 32.7 out of 100 (42nd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Interquim, S.A. focus on?

Interquim, S.A.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 9 patents, ranking #2,057 of 6,058 assignees active in that subclass. Grants appear in 14 CPC subclasses total.

Is Interquim, S.A.'s patent grant rate increasing or decreasing?

Interquim, S.A.'s recent grant velocity is -67% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Interquim, S.A.'s patents?

Interquim, S.A.'s patents average 11.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Interquim, S.A. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Interquim, S.A.

USPTO PatentsView assignee record - 17 granted patents across 14 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Interquim ranks #16,900 of 49,997 tracked US assignees by granted-patent volume, with 17 patents across 14 technology areas.

#16,900
of 49,997 US assignees by volume: 42nd percentile
by Innovation Score (32.7/100): 11.3
avg claims per patent: -67%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R16900 · Foreign Corporation #16,900 · 17 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 17 grants
MID-PACK #16,900/49,997
PHOTO-FINISH Iconix
CPC-FOCUS A61P · 14 areas
INNOV-THIN 32.7/100
CLAIMS-PAR 11.3 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -67% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Iconix, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Interquim’s 32.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.0 pts (31%) Velocity 2.7 pts (8%) Breadth 13.2 pts (40%) Claim depth 6.8 pts (21%)

Qualcomm Incorporated · highest

85
Interquim · this assignee

33
3D Lighting… · lowest

7

What this shows Interquim's Innovation Score is 32.7/100 (42nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Interquim?

Each dot is one of Interquim’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Interquim’s own 11.3 claims/patent is at or below the 12.5 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Interquim vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Interquim's grants concentrate

Interquim, S.A. is a focused PatentsView assignee: 14 CPC subclasses with 52.9% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (3 grants) versus a trough of 1 in 2017. By volume, Interquim sits between Intellivision Technologies Corp and Imaging Systems Technology, Inc..

Interquim's three-year grant acceleration

Interquim, S.A. shows 2 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Intellivision

17
Inter-university…

17
International Ins…

17
International Ref…

17
Ishikawa Gasket

17
IV

17
Iconix

17
Imaging Systems T…

17
Interquim ◀

17

What this shows Interquim holds 17 patents at rank #16,886, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Interquim

By rank, the assignees closest to #16,886 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Interquim's primary technology class.

Interquim's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 42nd percentile higher than 42% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Interquim, S.A. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	17.6%
2016	2	11.8%
2017	1	5.9%
2018	3	17.6%
2019	3	17.6%
2020	2	11.8%
2022	1	5.9%
2024	1	5.9%
2025partial year	1	5.9%

Which technologies does Interquim, S.A. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 9

C07D - Heterocyclic Compounds 8

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 4

C08G - Macromolecular Compounds Obtained Otherwise Than BY Reactions Only Involving Unsaturated Carbon-to-carbon Bonds 4

A61Q - Specific USE OF Cosmetics OR Similar Toiletry Preparations 4

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 4

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 2

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 1

C07C - Acyclic OR Carbocyclic Compounds 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

A23V - Indexing Scheme Relating TO Foods, Foodstuffs OR Non-alcoholic Beverages AND Lactic OR Propionic Acid Bacteria Used IN Foodstuffs OR Food Preparation 1

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 1

A23K - Fodder 1

C30B - Single-crystal Growth ; Unidirectional Solidification OF Eutectic Material OR Unidirectional Demixing OF Eutectoid MATERIAL; Refining BY Zone-melting OF Material ; Production OF A Homogeneous Polycrystalline Material With Defined Structure ; Single Crystals OR Homogeneous Polycrystalline Material WI 1

Top 14 of 14 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Interquim, S.A.'s patent record in context - here's where to go next.

Interquim, S.A.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 52.9% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #16,900 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Interquim, S.A. against Intellivision Technologies Corp, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 32.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.